[Long-term obsidan therapy of ischemic heart disease patients at high risk for sudden death].
To study the possibilities of long-term obsidan treatment of ischaemic heart disease (IHD) patients with high risk of sudden death 865 men aged 35-39 years with IHD were examined twice. After the examination including a 24-hour ECG monitoring and the tread-mill test 175 men were selected with grade 2 and over of ventricular extrasystole without contraindications to prolonged treatment with obsidan. The patients were divided into two groups: the treated group (with obsidan) and a control group without active treatment. The treatment with obsidan began with 40 mg/day, the dose being gradually increased. The daily dose was assessed as adequate for stable decrease of the heart rate by 15-20%. As a result of treatment it was possible to decrease the heart rate by 19.2%, on the average, in the control group it was 2.8%. Systolic and diastolic arterial pressure decreased in the first group by 11%, in the control group it rose by 4%. Improvement in angina pectoris course in the first group rose by 16%, in the other group only by 6%. A certain tendency has been recorded in the group of obsidan treated patients to lowering the number of those with 4-5 grades of ventricular extra-systole.
D000328:Adult; D000787:Angina Pectoris / Q000150:complications / Q000517:prevention & control*; D005117:Cardiac Complexes, Premature / Q000150:complications / Q000517:prevention & control*; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy*; D003645:Death, Sudden; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D005082:Physical Exertion; D011433:Propranolol / Q000008:administration & dosage*
D011433:Propranolol
Dlitel'noe lechenie obzidanom bol'nykh ishemicheskoĭ bolezn'iu serdtsa s vysokim riskom vnezapnoĭ smerti.